Did psilocybin beat SSRIs in clinical trials?

The 2021 Imperial College London trial found psilocybin therapy was comparable to escitalopram (Lexapro) on the primary outcome measure (QIDS depression scale), but psilocybin showed significantly greater improvements on secondary measures including emotional processing, wellbeing, and meaning. The trial was not powered to show superiority, but the effect sizes favoured psilocybin on most measures.

What did psilocybin do differently from SSRIs?

SSRIs produced emotional blunting — a flattening of both negative and positive emotions. Psilocybin produced the opposite: increased emotional range, greater ability to access positive emotions, and improvements in meaning and purpose. Participants in the psilocybin group reported feeling 'more like themselves' rather than emotionally muted.

Psilocybin vs SSRIs: What the Head-to-Head Trial Actually Found

In 2021, Imperial College London ran the first head-to-head trial of psilocybin against an SSRI. Here's what they found — and what it means for people who've tried antidepressants.

The Trial That Changed the Conversation

In April 2021, researchers at Imperial College London published the results of the first randomised controlled trial to directly compare psilocybin therapy against a selective serotonin reuptake inhibitor (SSRI) — specifically escitalopram (sold as Lexapro or Cipralex). The study, published in the New England Journal of Medicine, enrolled 59 patients with moderate-to-severe major depressive disorder and ran for six weeks.

The headline finding: psilocybin therapy was comparable to escitalopram on the primary outcome measure (the Quick Inventory of Depressive Symptomatology, or QIDS). But the secondary findings told a more nuanced story — and they are the reason this trial has been cited over 800 times since publication.

What the Numbers Actually Showed

On the QIDS primary measure, both groups showed significant improvement. The psilocybin group showed a mean reduction of 8.0 points; the escitalopram group showed 6.0 points. The difference was not statistically significant (the trial was not powered to show superiority), but the effect size favoured psilocybin.

On secondary measures, the differences were more pronounced:

Wellbeing (WEMWBS scale): Psilocybin group improved by 7.6 points vs 4.9 for escitalopram
Anhedonia (SHAPS scale): Psilocybin group showed significantly greater reduction in inability to feel pleasure
Psychological connectedness: Psilocybin group showed significantly greater improvements in sense of meaning and purpose
Emotional processing: Psilocybin group showed increased emotional range; escitalopram group showed emotional blunting

The emotional blunting finding is particularly significant. SSRIs are known to produce emotional blunting in a substantial proportion of patients — a flattening of both negative and positive emotions that many patients describe as worse than the depression itself. The psilocybin group showed the opposite effect: increased emotional range and greater access to positive emotions.

The Mechanism Difference

SSRIs work by increasing serotonin availability in the synaptic cleft — a blunt instrument that affects all serotonin-dependent processes simultaneously. The result is a gradual, generalised shift in mood that takes 4–6 weeks to manifest and requires daily dosing to maintain.

Psilocybin works differently. It binds directly to serotonin 2A receptors — particularly in the prefrontal cortex and default mode network — producing a temporary but profound shift in brain network connectivity. The 2022 fMRI study by Daws et al. in Nature Medicine showed that psilocybin therapy produced lasting increases in brain network flexibility that correlated directly with antidepressant response. This flexibility — the brain's ability to shift between different functional states — is precisely what depression reduces.

The key implication: SSRIs manage symptoms through continuous pharmacological intervention. Psilocybin appears to produce a reset — a change in the underlying network architecture that persists after the drug has cleared the system.

What This Means for People Who've Tried Antidepressants

Approximately 30–40% of people with major depression do not respond adequately to first-line antidepressant treatment. For this group — classified as treatment-resistant depression — the Imperial trial is particularly relevant. The psilocybin group in the trial included patients who had previously tried antidepressants without adequate response, and the effect sizes in this subgroup were at least as strong as in the overall population.

The practical implication: for people who have tried SSRIs and found them either ineffective or intolerable (due to side effects including emotional blunting, sexual dysfunction, or weight gain), psilocybin therapy represents a mechanistically distinct alternative with a different — and in some respects more favourable — side effect profile.

The Microdosing Bridge

For people who cannot access clinical psilocybin therapy, microdosing offers a sub-threshold approach that engages the same serotonin 2A receptor system without the full psychedelic experience. The 2021 Scientific Reports observational study found microdosers reported significantly lower depression and anxiety scores compared to non-microdosing controls, with improvements in emotional regulation and psychological wellbeing that parallel the secondary outcomes of the Imperial trial.

The standard protocol is 100–150mg psilocybin on a 4-on, 3-off schedule. Unlike SSRIs, microdosing does not require daily dosing to maintain effect — the rest days are built into the protocol to prevent receptor tolerance.

This article is for informational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before making any changes to your health regimen.